Received by email:

File: ATT_NR_Resignation_Appointment Final.docx

Abattis Announces Appointment of 
Raymond Cox, Andrea Bates & Barry Comis

Vancouver, BC - September 4, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT),
---> is a Company that develops and commercializes natural health (nutraceutical) products. Abattis conducts research and 
--->development to create plant-based (botanical) intellectual property, and ingredients for the pharmaceutical, nutraceut
--->ical, bioceutical and cosmetic markets; some of which will contain cannabinoid compounds. 
We would like to take this opportunity to announce the following resignations and appointments within the Company and 
--->its wholly owned subsidiaries. 
The appointment of Raymond Cox as President of Vergence Visionary Bioceuticals Corp. ("Vergence") effective September 
--->1, 2015. Mr.Cox is an entrepreneur, visionary, start up, sales and marketing leader for 20 years in "the direct to con
--->sumer and wellness industries". He has successfully changed 3 Canadian hair loss clinics in a positive direction. They
---> have grown to become 13 profitable International hair loss and hair removal clinics, which ultimately produced millio
--->ns of dollars in yearly revenue within 36 months. Furthermore, he has personally built online wellness organizations i
--->nto the 10's of thousands and influenced 100's of thousands through training, motivation and collaboration with key me
--->dical personnel. 
Andrea Bates will be joining the team as the Chief Operating Officer of Vergence.  Mrs. Bates, as co-founder of 10 Tho
--->usand BCtrademark Inc. has helped lead the research, team management, product marketing, brand development and design 
--->packaging. Her marketing and branding expertise has been an asset in website development, presentation materials, rese
--->arch and industry relations. As CMO, Andrea directs and provides communication of corporate vision, product branding a
--->nd development to the marketing and advertising team.  She is also involved in sales, export market development and co
--->rporate planning.
Her energetic marketing vision was instrumental in the development and launch of 10 Thousand BCtrademark Luxury Glacie
--->r Water.  Twenty-one days after the launch at the Sundance Film Festival, 10 Thousand BCtrademark appeared on ABC News
---> Good Morning America to an audience of 5.36M and was instantly positioned as a top luxury brand.  Since then 10 Thous
--->and BCtrademark has appeared in numerous magazines, TV Shows and Movies with virtually no advertising dollars spent!
Mr. Barry Comis was appointed to the Board of Directors of Abattis effective September 1, 2015.   Mr. Comis has spent 
--->the last eight years as Executive CP at Viero Group Ltd, where he remains in charge of Corporate Investment Capital an
--->d Corporate business consulting; specializing in offshore Fund management and investment acquisitions and mergers. Mr.
---> Comis is also the current owner and principal of Pure Logic Technologies Ltd., which is a 3d discrete event simulatio
--->n company that models large industrial plants or assists in the design of new operations. 
Mr. Brazos Minshew will be resigning as President of Biocell Labs Inc. ("Biocell") and Vergence as well as Chief Scien
--->ce Officer for Abattis. Mr. Minshew, however will not be leaving the Company. He will be assuming his new role on the 
--->Board of Directors of Abattis, all effective August 31, 2015. 
Emanuel  Montenegrino will also be resigning effective August 31, 2015 as a Director of the Company. The Company would
---> like to thank Mr. Montenegrino for all his services and wishes him the best in all his future endeavors. 
About Abattis Bioceuticals Corp. 
Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug
---> development industry.  The Company develops and licenses natural health products, medicines, extractions, and ingredi
--->ents for the biologics, nutraceutical, bioceutical, and cosmetic markets - some of which will contain cannabinoid comp
--->ounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly e
--->xpanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Ca
--->nada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
 ON BEHALF OF THE BOARD
"Bill Fleming" Bill Fleming, CEO
For further information, contact the Company at (604) 336-0881 or at news@abattis.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY 
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words "antic
--->ipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are in
--->tended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on 
--->which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-look
--->ing statements because the Company can give no assurance that they will prove to be correct. Since forward-looking sta
--->tements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Thes
--->e statements speak only as of the date of this press release. Actual results could differ materially from those curren
--->tly anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Disc
--->ussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertak
--->e to update this information at any particular time.


File: ATT_NR_Resignation_Appointment Final.pdf


  
Suite
  1040
   
  885
  West
  Georgia
  Street,
  
  
Vancouver,
  BC
  
  
  V6C
  3H1
  
Tel:
  604.336.0881
  
Email:
  news@abattis.com
  

  

  


  
                                              Abattis
  Announces
  Appointment
  of
  
  
                                           Raymond
  Cox,
  Andrea
  Bates
  &
  Barry
  Comis
  

  
Vancouver,
  BC
   
  September
  4,
  2015
  -
  Abattis
  Bioceuticals
  Corp.
  (the
  "Company"
  or
  "Abattis")
  (OTCQX:
  ATTBF)
  (CSE:
  ATT),
  
is
  a
  Company
  that
  develops
  and
  commercializes
  natural
  health
  (nutraceutical)
  products.
  Abattis
  conducts
  research
  and
  
development
  to
  create
  plant-based
  (botanical)
  intellectual
  property,
  and
  ingredients
  for
  the
  pharmaceutical,
  nutraceutical,
  
bioceutical
  and
  cosmetic
  markets;
  some
  of
  which
  will
  contain
  cannabinoid
  compounds.
  
  

We
  would
  like
  to
  take
  this
  opportunity
  to
  announce
  the
  following
  resignations
  and
  appointments
  within
  the
  Company
  and
  
its
  wholly
  owned
  subsidiaries.
  
  

The
  appointment
  of
  Raymond
  Cox
  as
  President
  of
  Vergence
  Visionary
  Bioceuticals
  Corp.
  ("Vergence")
  effective
  September
  
1,
  2015.
  Mr.Cox
  is
  an
  entrepreneur,
  visionary,
  start
  up,
  sales
  and
  marketing
  leader
  for
  20
  years
  in
  "the
  direct
  to
  consumer
  
and
  wellness
  industries".
  He
  has
  successfully
  changed
  3
  Canadian
  hair
  loss
  clinics
  in
  a
  positive
  direction.
  They
  have
  grown
  to
  
become
  13
  profitable
  International
  hair
  loss
  and
  hair
  removal
  clinics,
  which
  ultimately
  produced
  millions
  of
  dollars
  in
  yearly
  
revenue
  within
  36
  months.
  Furthermore,
  he
  has
  personally
  built
  online
  wellness
  organizations
  into
  the
  10's
  of
  thousands
  
and
  influenced
  100's
  of
  thousands
  through
  training,
  motivation
  and
  collaboration
  with
  key
  medical
  personnel.
  
  

Andrea
  Bates
  will
  be
  joining
  the
  team
  as
  the
  Chief
  Operating
  Officer
  of
  Vergence.
  
  Mrs.
  Bates,
  as
  co-founder
  of
  10
  Thousand
  
BCtrademark
  Inc.
  has
  helped
  lead
  the
  research,
  team
  management,
  product
  marketing,
  brand
  development
  and
  design
  packaging.
  
Her
  marketing
  and
  branding
  expertise
  has
  been
  an
  asset
  in
  website
  development,
  presentation
  materials,
  research
  and
  
industry
  relations.
  As
  CMO,
  Andrea
  directs
  and
  provides
  communication
  of
  corporate
  vision,
  product
  branding
  and
  
development
  to
  the
  marketing
  and
  advertising
  team.
  
  She
  is
  also
  involved
  in
  sales,
  export
  market
  development
  and
  
corporate
  planning.
  

Her
  energetic
  marketing
  vision
  was
  instrumental
  in
  the
  development
  and
  launch
  of
  10
  Thousand
  BCtrademark
  Luxury
  Glacier
  Water.
  
  
Twenty-one
  days
  after
  the
  launch
  at
  the
  Sundance
  Film
  Festival,
  10
  Thousand
  BCtrademark
  appeared
  on
  ABC
  News
  Good
  Morning
  
America
  to
  an
  audience
  of
  5.36M
  and
  was
  instantly
  positioned
  as
  a
  top
  luxury
  brand.
  
  Since
  then
  10
  Thousand
  BCtrademark
  has
  
appeared
  in
  numerous
  magazines,
  TV
  Shows
  and
  Movies
  with
  virtually
  no
  advertising
  dollars
  spent!
  

Mr.
  Barry
  Comis
  was
  appointed
  to
  the
  Board
  of
  Directors
  of
  Abattis
  effective
  September
  1,
  2015.
  
  

  
Mr.
  Comis
  has
  spent
  the
  last
  eight
  years
  as
  Executive
  CP
  at
  Viero
  Group
  Ltd,
  where
  he
  remains
  in
  charge
  of
  Corporate
  
Investment
  Capital
  and
  Corporate
  business
  consulting;
  specializing
  in
  offshore
  Fund
  management
  and
  investment
  
acquisitions
  and
  mergers.
  Mr.
  Comis
  is
  also
  the
  current
  owner
  and
  principal
  of
  Pure
  Logic
  Technologies
  Ltd.,
  which
  is
  a
  3d
  
discrete
  event
  simulation
  company
  that
  models
  large
  industrial
  plants
  or
  assists
  in
  the
  design
  of
  new
  operations.
  
  

Mr.
  Brazos
  Minshew
  will
  be
  resigning
  as
  President
  of
  Biocell
  Labs
  Inc.
  ("Biocell")
  and
  Vergence
  as
  well
  as
  Chief
  Science
  
Officer
  for
  Abattis.
  Mr.
  Minshew,
  however
  will
  not
  be
  leaving
  the
  Company.
  He
  will
  be
  assuming
  his
  new
  role
  on
  the
  Board
  
of
  Directors
  of
  Abattis,
  all
  effective
  August
  31,
  2015.
  
  

Emanuel
  
  Montenegrino
  will
  also
  be
  resigning
  effective
  August
  31,
  2015
  as
  a
  Director
  of
  the
  Company.
  The
  Company
  would
  
like
  to
  thank
  Mr.
  Montenegrino
  for
  all
  his
  services
  and
  wishes
  him
  the
  best
  in
  all
  his
  future
  endeavors.
  
  
 
  
Suite
  1040
   
  885
  West
  Georgia
  Street,
  
  
Vancouver,
  BC
  
  
  V6C
  3H1
  
Tel:
  604.336.0881
  
Email:
  news@abattis.com
  

  

  


  
About
  Abattis
  Bioceuticals
  Corp.
  
  

Abattis
  is
  a
  specialty
  biotechnology
  company
  that
  aggregates,
  incubates,
  integrates,
  and
  invests
  in
  the
  botanical
  drug
  
development
  industry.
  
  The
  Company
  develops
  and
  licenses
  natural
  health
  products,
  medicines,
  extractions,
  and
  
ingredients
  for
  the
  biologics,
  nutraceutical,
  bioceutical,
  and
  cosmetic
  markets
   
  some
  of
  which
  will
  contain
  cannabinoid
  
compounds.
  The
  Company
  also
  has
  an
  extensive
  pipeline
  of
  high-quality
  products
  and
  intellectual
  property
  for
  the
  rapidly
  
expanding
  botanical
  drug
  market.
  We
  follow
  strict
  standard
  operating
  protocols,
  and
  adhere
  to
  the
  applicable
  laws
  of
  
Canada
  and
  foreign
  jurisdictions.
  For
  more
  information,
  visit
  the
  Company's
  website
  at:
  www.abattis.com.
  


  
ON
  BEHALF
  OF
  THE
  BOARD
  

"Bill
  Fleming"
  
Bill
  Fleming,
  CEO
  

For
  further
  information,
  contact
  the
  Company
  at
  (604)
  336-0881
  or
  at
  news@abattis.com.
  

NEITHER
  THE
  CANADIAN
  SECURITIES
  EXCHANGE
  NOR
  ITS
  REGULATIONS
  SERVICES
  PROVIDER
  HAVE
  REVIEWED
  OR
  ACCEPT
  
RESPONSIBILITY
  FOR
  THE
  ADEQUACY
  OR
  ACCURACY
  OF
  THIS
  RELEASE.
  

FORWARD
  LOOKING
  INFORMATION
  
This
  press
  release
  contains
  forward-looking
  statements.
  The
  use
  of
  any
  of
  the
  words
  "anticipate",
  "continue",
  "estimate",
  "expect",
  "may",
  "will",
  
"project",
  "should",
  "believe"
  and
  similar
  expressions
  are
  intended
  to
  identify
  forward-looking
  statements.
  Although
  the
  Company
  believes
  that
  the
  
expectations
  and
  assumptions
  on
  which
  the
  forward-looking
  statements
  are
  based
  are
  reasonable,
  undue
  reliance
  should
  not
  be
  placed
  on
  the
  forward-
looking
  statements
  because
  the
  Company
  can
  give
  no
  assurance
  that
  they
  will
  prove
  to
  be
  correct.
  Since
  forward-looking
  statements
  address
  future
  events
  
and
  conditions,
  by
  their
  very
  nature
  they
  involve
  inherent
  risks
  and
  uncertainties.
  These
  statements
  speak
  only
  as
  of
  the
  date
  of
  this
  press
  release.
  Actual
  
results
  could
  differ
  materially
  from
  those
  currently
  anticipated
  due
  to
  a
  number
  of
  factors
  and
  risks
  various
  risk
  factors
  discussed
  in
  the
  Company's
  
Management's
  Discussion
  and
  Analysis
  under
  the
  Company's
  profile
  on
  www.sedar.com.
  While
  the
  Company
  may
  elect
  to,
  it
  does
  not
  undertake
  to
  update
  
this
  information
  at
  any
  particular
  time.